Commonwealth Equity Services’s Novavax NVAX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$519K Sell
55,055
-695
-1% -$6.23K ﹤0.01% 3287
2026
Q1
$454K Buy
55,750
+5,652
+11% +$51.2K ﹤0.01% 3294
2025
Q4
$337K Sell
50,098
-174
-0.3% -$1.31K ﹤0.01% 3554
2025
Q3
$436K Sell
50,272
-5,791
-10% -$45.1K ﹤0.01% 3296
2025
Q2
$353K Buy
56,063
+5,543
+11% +$36.7K ﹤0.01% 3449
2025
Q1
$324K Buy
50,520
+7,486
+17% +$61.9K ﹤0.01% 3425
2024
Q4
$346K Buy
43,034
+3,236
+8% +$31.2K ﹤0.01% 3290
2024
Q3
$503K Sell
39,798
-3,639
-8% -$47K ﹤0.01% 2887
2024
Q2
$550K Sell
43,437
-21,182
-33% -$213K ﹤0.01% 2757
2024
Q1
$309K Buy
64,619
+46,311
+253% +$215K ﹤0.01% 3248
2023
Q4
$88K Buy
18,308
+1,001
+6% +$6.13K ﹤0.01% 3690
2023
Q3
$125K Buy
17,307
+2,201
+15% +$17.6K ﹤0.01% 3524
2023
Q2
$112K Buy
15,106
+1,809
+14% +$14.2K ﹤0.01% 3554
2023
Q1
$92K Sell
13,297
-15
-0.1% -$138 ﹤0.01% 3506
2022
Q4
$136K Buy
13,312
+1,804
+16% +$31.8K ﹤0.01% 3350
2022
Q3
$209K Sell
11,508
-1,703
-13% -$73.8K ﹤0.01% 3129
2022
Q2
$679K Buy
13,211
+2,050
+18% +$106K ﹤0.01% 2195
2022
Q1
$822K Sell
11,161
-1,603
-13% -$143K ﹤0.01% 2136
2021
Q4
$1.83M Buy
12,764
+171
+1% +$29.4K ﹤0.01% 1558
2021
Q3
$2.61M Buy
12,593
+2,746
+28% +$605K 0.01% 1274
2021
Q2
$2.09M Buy
9,847
+213
+2% +$39K 0.01% 1391
2021
Q1
$1.75M Sell
9,634
-3,117
-24% -$621K ﹤0.01% 1420
2020
Q4
$1.42M Sell
12,751
-2,703
-17% -$287K ﹤0.01% 1426
2020
Q3
$1.67M Buy
15,454
+5,577
+56% +$679K 0.01% 1194
2020
Q2
$823K Sell
9,877
-4,710
-32% -$180K ﹤0.01% 1546
2020
Q1
$198K Buy
14,587
+1,236
+9% +$10.5K ﹤0.01% 2399
2019
Q4
$53K Buy
+13,351
New +$57.9K ﹤0.01% 2795
2019
Q2
Sell
-5,928
Closed -$65K 2802
2019
Q1
$65K Sell
5,928
-10,592
-64% -$334K ﹤0.01% 2646
2018
Q4
$607K Buy
16,520
+675
+4% +$26.2K ﹤0.01% 1509
2018
Q3
$595K Sell
15,845
-933
-6% -$26.3K ﹤0.01% 1671
2018
Q2
$450K Sell
16,778
-181
-1% -$6.12K ﹤0.01% 1829
2018
Q1
$712K Buy
16,959
+2,315
+16% +$93K ﹤0.01% 1460
2017
Q4
$363K Sell
14,644
-283
-2% -$6.9K ﹤0.01% 1915
2017
Q3
$340K Sell
14,927
-32
-0.2% -$716 ﹤0.01% 1877
2017
Q2
$344K Buy
14,959
+1,560
+12% +$30.6K ﹤0.01% 1824
2017
Q1
$343K Buy
13,399
+122
+0.9% +$3.35K ﹤0.01% 1764
2016
Q4
$335K Buy
13,277
+1,125
+9% +$32.8K ﹤0.01% 1702
2016
Q3
$506K Buy
12,152
+1,574
+15% +$203K ﹤0.01% 1374
2016
Q2
$1.54M Buy
10,578
+2,259
+27% +$259K 0.01% 768
2016
Q1
$858K Buy
8,319
+1,071
+15% +$115K 0.01% 1024
2015
Q4
$1.22M Buy
7,248
+397
+6% +$61.1K 0.01% 832
2015
Q3
$969K Buy
6,851
+640
+10% +$144K 0.01% 911
2015
Q2
$1.38M Sell
6,211
-60
-1% -$10.5K 0.01% 784
2015
Q1
$1.04M Buy
6,271
+335
+6% +$54.4K 0.01% 932
2014
Q4
$704K Buy
5,936
+765
+15% +$80K 0.01% 1080
2014
Q3
$431K Buy
5,171
+750
+17% +$67.8K 0.01% 1339
2014
Q2
$409K Buy
4,421
+1,000
+29% +$87.9K 0.01% 1361
2014
Q1
$310K Buy
3,421
+49
+1% +$5.47K ﹤0.01% 1441
2013
Q4
$345K Buy
3,372
+2,250
+201% +$159K 0.01% 1352
2013
Q3
$71K Buy
+1,122
New +$63.2K ﹤0.01% 1784

Other funds holding NVAX

Commonwealth Equity Services's NVAX Position: Q2 2026 in Review

Commonwealth Equity Services reduced its Novavax (NVAX) stake by 1.2% in Q2 2026, selling an estimated $6.23K and leaving 55,055 shares worth $519K. The position accounts for ﹤0.01% of the portfolio, ranked #3287.

Commonwealth Equity Services first reported a position in NVAX in Q3 2013 and has held it in 50 quarters since. The position peaked at $2.61M in Q3 2021. 266 funds tracked by Wall St. Rank hold NVAX as of Q2 2026.

  • Commonwealth Equity Services held 55,055 shares of Novavax worth $519K as of Q2 2026.
  • Commonwealth Equity Services sold 695 Novavax shares in Q2 2026, an estimated $6.23K.
  • Novavax made up ﹤0.01% of Commonwealth Equity Services's portfolio in Q2 2026, its #3287 holding.
  • Commonwealth Equity Services first reported a position in Novavax in Q3 2013 and has held it in 50 quarters since.
  • Commonwealth Equity Services's Novavax position peaked at $2.61M in Q3 2021.
  • 266 funds tracked by Wall St. Rank held Novavax as of Q2 2026.

Based on Commonwealth Equity Services's 13F filing for Q2 2026, filed 29 Jul 2026.